<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2618</td>
<td>Exosomal microRNAs in hepatocellular carcinoma</td>
<td>Zheng BH, Ni XJ, Liu HB</td>
</tr>
<tr>
<td>2621</td>
<td>Transjugular intrahepatic portosystemic shunt for recompensating decompensated cirrhosis?</td>
<td>Karagiannakis DS</td>
</tr>
<tr>
<td>2624</td>
<td>Metadherin-driven promotion of cancer stem cell phenotypes and its effect on immunity in hepatocellular carcinoma</td>
<td>Todorović N, Amedei A</td>
</tr>
<tr>
<td>2629</td>
<td>Validation of adherence prediction system for lifestyle interventions in nonalcoholic fatty liver disease</td>
<td>Chisthi MM</td>
</tr>
<tr>
<td>2633</td>
<td>Impact of lifestyle interventions on pathogenesis of nonalcoholic fatty liver disease</td>
<td>Ezzat WM</td>
</tr>
<tr>
<td>2638</td>
<td>Latest insights into the global epidemiological features, screening, early diagnosis and prognosis prediction of esophageal squamous cell carcinoma</td>
<td>Zhao YX, Zhao HP, Zhao MY, Yu Y, Qi X, Wang JH, Lv J</td>
</tr>
<tr>
<td>2657</td>
<td>Development and validation of a new prognostic model for patients with acute-on-chronic liver failure in intensive care unit</td>
<td>Zhu ZY, Huang XH, Jiang HQ, Liu L</td>
</tr>
<tr>
<td>2689</td>
<td>Kinesin 26B modulates M2 polarization of macrophage by activating cancer-associated fibroblasts to aggravate gastric cancer occurrence and metastasis</td>
<td>Huang LM, Zhang MJ</td>
</tr>
</tbody>
</table>
Hydrogen-rich water alleviates constipation by attenuating oxidative stress through the sirtuin1/nuclear factor-erythroid-2-related factor 2/heme oxygenase-1 signaling pathway


LETTER TO THE EDITOR

Colorectal cancer screening: The value of early detection and modern challenges

Li J, Li ZP, Ruan WJ, Wang W

Downstaging strategies for unresectable hepatocellular carcinoma

Karachaliou GS, Dimitrokallis N, Moris DP
ABOUT COVER
Editorial Board Member of World Journal of Gastroenterology, Khaled A Jadallah, MD, Associate Professor Consultant Gastroenterologist, Department of Internal Medicine, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan. khaled.j@just.edu.jo

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG’s CiteScore for 2021 is 8.3.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yu-Xi Chen; Production Department Director: Xiang Li; Cover Editor: Jia-Ru Fan.
Downstaging strategies for unresectable hepatocellular carcinoma

Georgia Sofia Karachaliou, Nikolaos Dimitrokallis, Dimitrios P Moris

Abstract

A significant number of patients with hepatocellular carcinoma (HCC) are usually diagnosed in advanced stages, that leads to inability to achieve cure. Palliative options are focusing on downstaging a locally advanced disease. It is well-supported in the literature that patients with HCC who undergo successful conversion therapy followed by curative-intent surgery may achieve a significant survival benefit compared to those who receive chemotherapy alone or those who are successfully downstaged with conversion therapy but not treated with surgery. Hepatic artery infusion chemotherapy can be a potential downstaging strategy, since recent studies have demonstrated excellent outcomes in patients with colorectal liver metastatic disease as well as primary liver malignancies.

Key Words: Unresectable hepatocellular carcinoma; Hepatic arterial infusion chemotherapy; Downstaging; Hepatocellular carcinoma

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
TO THE EDITOR

We read with great interest the meta-analysis from Cao et al.[1] showing that triple therapy, including hepatic artery infusion chemotherapy (HAIC) combined with angiogenesis inhibitors and programmed cell death protein 1/programmed death ligand 1 blockers (AIPB) were able to increase the survival in cases of unresectable hepatocellular carcinoma (uHCC) more than AIPB regimes. This meta-analysis strongly suggested that HAIC-based treatments are likely to be the best choice for uHCC.

We agree with the conclusions of the authors and the urge for analyses at the cellular level and additional large-scale randomized controlled trials[2]. It is well known that HCC is the most common primary liver cancer[2]. Even though treatment of early HCC seems to achieve cure in most patients, unfortunately, a significant number of patients with HCC are diagnosed in advanced stages[3]. This fact leads to inability to achieve cure. Palliative options are focusing on downstaging a locally advanced disease. In their meta-analysis, the authors did not present strong data about the rate of conversion to resectability, if any, in the group of patients with unresectable, liver confined, disease for both the triple therapy and the AIPB groups. We suspect that some patients could become eligible for locoregional therapies after downstaging, that will revolutionize and liberalize treatment options for this category of HCC patients. It is well-supported in the literature that patients with HCC who undergo successful downstaging therapy followed by curative-intent surgery may achieve a significant survival advantage compared to those who receive chemotherapy only or those who are successfully downstaged without being followed by surgery. As the authors highlighted, even if the success rate of conversion varies greatly, ranging from 0.8% to 60% and depending on the therapeutic protocols, combined locoregional and systemic downstaging treatment shows significant benefit, with a downstaging rate of up to 60% and a disease stability rate of up to 100%[4].

Moreover, the authors omitted to acknowledge the difficulties starting and maintaining a HAI-pump program. Popularization and development of HAI pump chemotherapy programs has been limited by logistic and feasibility concerns. Despite recent studies demonstrating excellent outcomes in patients with colorectal liver metastatic disease as well as primary liver malignancies[5], many challenges are encountered when building that mainly have to do with lack of multidisciplinary care, lack of access to device/equipment access and chemotherapeutic drugs[6]. Another concern about the popularity of HAIC is the fact that its safety and efficacy has been limited to centers of excellence increasing the number of new HAI programs emerging across the world. In the same vein, as HAI programs continue to develop and evolve and consider pump as an available downstaging modality, it is of paramount importance to develop a quality frame for HAI utilization that could lead to optimization regarding safety of patients and minimization of toxicity.

FOOTNOTES

Author contributions: Karachaliou GS and Moris DP designed the research study; Dimitrokallis N and Moris DP performed the research; Karachaliou GS and Moris DP analyzed the data and wrote the manuscript; and all authors have read and approve the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country of origin: United States

ORCID number: Georgia Sofia Karachaliou 0000-0003-4091-3798; Dimitrios P Moris 0000-0002-5276-0699.

S-Editor: Wang JJ
L-Editor: A
P-Editor: Chen YX

REFERENCES


